Patents by Inventor John Feutrill

John Feutrill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230121337
    Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.
    Type: Application
    Filed: June 24, 2022
    Publication date: April 20, 2023
    Inventors: Louise Clare Kirman, Carl Eric Schwartz, Wojtek Michowski, Dale A. Porter, JR., Justin Ripper, John Feutrill
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230109076
    Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 6, 2023
    Inventors: Louise Clare KIRMAN, Carl Eric SCHWARTZ, Wojtek MICHOWSKI, Dale A. PORTER, Justin RIPPER, John FEUTRILL, John Paul SHERRILL, Thomas P. BLAISDELL
  • Synthesis of polyaryl substituted aryl compounds
    Patent number: 10793495
    Abstract: A method for the synthesis of a aryl compound of Formula (1).
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: October 6, 2020
    Assignee: Boulos & Cooper Pharmaceuticals Pty Ltd
    Inventors: Ramiz Boulos, John Feutrill
  • Tetrahydroisoquinoline derived PRMT5-inhibitors
    Patent number: 10494376
    Abstract: A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 3, 2019
    Assignee: CTXT PTY. LTD.
    Inventors: Ylva Elisabet Bergman, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Graeme Irvine Stevenson, Paul Anthony Stupple
  • Benzodiazepines as bromodomain inhibitors
    Patent number: 10167292
    Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 1, 2019
    Assignee: Catalyst Therapeutics Pty Ltd.
    Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe
  • Benzodiazepines as bromodomain inhibitors
    Publication number: 20180230153
    Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 16, 2018
    Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe
  • SYNTHESIS OF ARYL COMPOUNDS
    Publication number: 20180215687
    Abstract: A method for the synthesis of a aryl compound of Formula (1).
    Type: Application
    Filed: August 8, 2016
    Publication date: August 2, 2018
    Inventors: Ramiz Boulos, John Feutrill
  • Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
    Patent number: 10005792
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 26, 2018
    Assignee: CTXT PTY. LTD.
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS
    Publication number: 20170313713
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R1 and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: November 2, 2017
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS
    Publication number: 20170298075
    Abstract: A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 19, 2017
    Inventors: Ylva Elisabet Bergman, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Graeme Irvine Stevenson, Paul Anthony Stupple
  • FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS
    Publication number: 20170166555
    Abstract: The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 15, 2017
    Inventors: Ian James, Ian Dixon, John Feutrill, Anthony Cuzzupe, Herbert Treutlein, Jun Zeng, Tracy Nero, Peter Gunning
  • Aniline derivatives, their preparation and their therapeutic application
    Patent number: 9624159
    Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: April 18, 2017
    Assignee: SANOFI
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    Publication number: 20160199330
    Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: December 14, 2015
    Publication date: July 14, 2016
    Inventors: John FEUTRILL, Caroline LERICHE, David MIDDLEMISS
  • Aniline derivatives, their preparation and their therapeutic application
    Patent number: 9249085
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: February 2, 2016
    Assignee: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    Publication number: 20140350019
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss